Jupiter clinical trial looks at the treatment of ovarian cancer

Jupiter – Jupiter Medical Center registration of patients in clinical trials to review studies for ladies with platinum-sensitive ovarian cancer that recurred.

It sponsors research and looks at Morphotek monoclonal antibodies-farletuzumab – which also may block tumor cell protein in development of platinum-sensitive ovarian cancer.

Researchers want to find out if a new drug may extend the duration of the second remission in addresses that are returned after six months of their most recent treatment.

A lot more facts get (561) 745-5768.

This entry was posted on Wednesday, 16 March 2010 at 12: 38 am and is filed under treatment. You can follow any responses to this entry through the RSS 2.0. You can leave a response, or trackback from your own site.